2010 - TTS International Congress


Clinical Immunosuppression Kidney late

19.17 - Everolimus (EVE) in maintenance renal transplant recipients converted from calcineurin inhibitors (CNI) immunosuppression treatment

Presenter: Manuel, Rengel, Madrid, Spain
Authors: Rengel M., Verdalles


EVEROLIMUS (EVE) IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS CONVERTED FROM CALCINEURIN INHIBITORS (CNI) IMMUNOSUPPRESSION TREATMENT

CLINICAL IMMUNOSUPPRESSION - KIDNEY LATE

M. Rengel1, . Verdalles2, A. Vega2, S. Abad2, E. Verde2
1Nephrology, Hospital General Universitario Gregorio Marañón, Madrid/SPAIN, 2Nephrology, Hospital General Universitario, Madrid/SPAIN

Body: Introduction:Everolimus is a proliferation signal inhibitor utilized as immunosupressant in combination with CNI in renal transplantation. The present paper reports ourexperience with renal grafted patients treated with CNI who were switched to EVE in order to avoid CNI nephrotoxicity. Methods:From february 2005, 120 cadaver kidney graftedpatients (82 men and 38 women) were switched from CNI to EVE. The age of the patients was 56+/-15 years, with 8.5+/-6 years (1-23) followup period. The immunosuppression treatment was based onPrednisone, Mycophenolate Mophetil/Sodium Mycophenolic Acid and Tacrolimus/Cyclosporine. CNI was stopped according to an abrupt conversion protocol. EVE was started at 1.0 mg day divided in two dosesand blood concentration was maintained between 3-5 ng/ml. Results: At 2 year patient and graft survival was 100% and there were not acute rejection episodes. Blood presure showsno changes and there were not changes in glucose metabolism. Lipids increased slightly during the first three months after EVE treatment. Proteinuria apear in patients with previos glomerularlesions. GFR improved in 55% of patients. In conclusion: conversion from CNI to EVE in renal transplant patients is safe and affect slightly to lipids metabolism

Disclosure: All authors have declared no conflicts of interest.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi